Amgen Braces for Rising Expenses Ahead of Q3 Results—Is a Profit Squeeze Looming?
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Amgen (NASDAQ:AMGN | AMGN Price Prediction) is expected to report third-quarter results on Tuesday, November 3, after the close. The stock is up 41.28% year to date, and management has already warned that spending will jump. The key question is whether revenue momentum can cover the higher costs.
Strong Momentum Meets a Spending Warning
Last quarter, Amgen posted non-GAAP EPS of $6.29 against a $5.62 consensus, its fifth consecutive beat. Revenue reached $10.05 billion, up 9.7% year over year and ahead of the $9.42 billion estimate. Full-year guidance was then raised to $38.2 billion to $39.4 billion in revenue and $22.30 to $23.50 in non-GAAP EPS.
The warning came from outgoing CFO Peter Griffith, who said on his final call that Amgen expects a “meaningful sequential increase in operating expenses in the third quarter.” That includes a $100 million upfront payment tied to a business-development deal, booked to R&D. Non-GAAP operating margin already slid 0.5 percentage points in Q2, while the tax rate rose 1.4 percentage points.
Consensus Points to Slower Profit Growth
| Metric | Consensus | Prior-Year Actual | YoY Growth |
|---|---|---|---|
| Q3 2026 Normalized EPS | $5.7876 | $5.64 | 2.6% |
| Q3 2026 Revenue | $10.08 billion | $9.56 billion | 5.4% |
| FY2026 Normalized EPS | $23.0343 | $21.84 | 5.5% |
| FY2026 Revenue | $38.97 billion | $36.74 billion | 6.1% |
Margins, MariTide and the Legacy Drag Will Decide This Quarter
The consensus math frames the squeeze. Analysts expect revenue growth of 5.4% but EPS growth of only 2.6%, and the EPS estimate sits below Q2’s $6.29. Operating margin will be the first metric to check, since management guided full-year non-GAAP margin to roughly 45% to 46% of product sales versus 48% in Q2.
R&D is the main driver. Full-year non-GAAP R&D should grow high single digits, funding 9 ongoing global Phase III MariTide trials alongside olpasiran and xaluritamig. Updates on MariTide enrollment and manufacturing expansion will be worth tracking, with capex guided to about $2.6 billion.
On the top line, Repatha ($953 million, +37%), EVENITY ($714 million, +38%) and TEZSPIRE ($486 million, +42%) must keep making up for legacy erosion. Prolia fell 32% and XGEVA 34% on biosimilar competition, Kyprolis dropped 17%, and Enbrel faces Medicare Part D price setting. IMDELLTRA, up 115%, deserves attention as it expands into Europe and China.
Leverage matters too. With $57.3 billion in debt and no buybacks in Q1 or Q2, I want to hear how Thomas Dittrich, set to succeed Griffith as CFO, frames capital allocation.
A Test of Whether Investment Can Pay for Itself
Amgen has gained 59.94% over the past year, so the bar is high. Management frames rising expenses as deliberate investment in MariTide, late-stage programs and commercial brands. If revenue holds and the raised guidance stays intact, that argument gets stronger. If margins contract faster than the 45% to 46% guide implies, the debate shifts from growth to profitability. This report will show how much of tomorrow’s pipeline today’s sales can fund.
Contact [email protected] for any questions or corrections.








